KP Tissue (KPT) AI Stock Analysis

• Market Cap: C$94.28M
• Dividend Yield: 6.86%
• Average Volume (3M): 17.75K
• Price to Earnings (P/E): 21.3
• Beta (1Y): 0.27
• Revenue Growth: N/A
• EPS Growth: -39.19%
• Country: CA
• Employees: 2,700
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.84
• Shares Outstanding: 10,008,159
• 10 Day Avg. Volume: 14,081
• 30 Day Avg. Volume: 17,752
• PEG Ratio: -0.23
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$10.00
• Price Target Upside: 6.84% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: ―

KP Tissue's overall stock score reflects a mix of strengths and challenges. The strong balance sheet and positive earnings call outlook are significant positives, enhancing stability and growth potential. However, profitability issues, high P/E ratio, and mixed technical indicators present cautionary elements. The attractive dividend yield provides some valuation support, but overall, the stock's performance hinges on continued operational improvements and strategic execution amid external challenges.

Positive Factors

Revenue Growth

Achieving record revenue reflects strong market demand and effective sales strategies, indicating a robust growth trajectory for the company.

Strong Balance Sheet

A strong balance sheet with no leverage enhances financial stability and provides flexibility for future investments and growth opportunities.

Market Share Expansion

Increasing market share in the facial tissue category strengthens competitive positioning and supports long-term revenue growth.

Negative Factors

Profitability Challenges

Ongoing profitability challenges can hinder reinvestment in growth initiatives and impact long-term financial health.

Tariff Exposure

Significant tariff exposure poses a risk to cost structures and pricing strategies, potentially affecting margins and profitability.

Decline in Consumer EBITDA Margin

A declining EBITDA margin in the consumer segment suggests pressure on cost management and pricing power, impacting overall profitability.

KP Tissue Business Overview & Revenue Model

Company Description

KP Tissue Inc. (KPT) is a Canadian company that focuses on managing its interest in Kruger Products L.P., a leading manufacturer and distributor of quality tissue products for both consumer and away-from-home markets. The company operates primarily in the consumer goods sector, providing a wide array of products such as bathroom tissue, facial tissue, paper towels, and napkins under popular brands like Cashmere, Purex, Scotties, and SpongeTowels.

How the Company Makes Money

KP Tissue makes money through its equity interest in Kruger Products L.P., which generates revenue by manufacturing and distributing tissue products across North America. The company earns money by selling these products to major retailers, wholesalers, and commercial clients. Key revenue streams include sales from branded consumer products and private label offerings. Additionally, Kruger Products L.P. engages in strategic partnerships and has a robust distribution network that enhances its market reach, thereby contributing to its earnings.

KP Tissue Financial Statement Overview

Summary

KP Tissue's financial performance is mixed. The balance sheet is robust with no leverage, enhancing stability and scoring high. However, the income statement reveals profitability issues with historical losses, and cash flow analysis shows variability, indicating potential instability. The overall financial picture is cautiously optimistic but with significant challenges.

Income Statement

The income statement shows consistent challenges with profitability, as evidenced by negative EBIT in most periods. The company managed a positive net income in TTM (Trailing-Twelve-Months) but has faced historical losses. Revenue data is missing, making margin analysis impossible.

Balance Sheet

The balance sheet is strong with zero debt, reflected in a favorable debt-to-equity ratio. The equity ratio is high, indicating a stable financial structure. The company has maintained healthy stockholders' equity over the years.

Cash Flow

Cash flow analysis shows variability, with operating cash flow improving in TTM (Trailing-Twelve-Months). Free cash flow was positive in the latest period, but historical fluctuations suggest potential instability in cash management. The operating cash flow to net income ratio indicates some operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	76.09M	264.78M	238.61M	115.99M	153.43M	197.84M
Net Income	4.43M	2.43M	-4.94M	-10.25M	1.24M	-1.95M
Balance Sheet
Total Assets	70.52M	71.31M	70.61M	81.71M	80.72M	71.31M
Cash, Cash Equivalents and Short-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.80M	1.80M	2.25M	7.68M	4.85M	4.99M
Stockholders Equity	68.72M	69.52M	68.36M	74.03M	75.87M	66.33M
Cash Flow
Free Cash Flow	0.00	0.00	6.98M	6.62M	1.15M	-2.44M
Operating Cash Flow	0.00	0.00	6.98M	6.62M	1.15M	-2.44M
Investing Cash Flow	6.97M	6.97M	6.98M	6.62M	5.56M	5.59M
Financing Cash Flow	-5.23M	-6.97M	-6.98M	-6.62M	-5.56M	-5.59M

KP Tissue Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KPT, the sentiment is Positive. The current price of 9.36 is below the 20-day moving average (MA) of 9.90, below the 50-day MA of 9.60, and above the 200-day MA of 8.74, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 78.46 is Negative, neither overbought nor oversold. The STOCH value of 92.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:KPT.

KP Tissue Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRU	78 Outperform	C$20.12B	20.23	14.48%	1.48%	3.71%	12.40%
EMP.A	70 Outperform	C$11.24B	16.30	12.97%	1.65%	1.96%	9.26%
RSI	70 Outperform	C$791.75M	11.41	14.63%	6.09%	6.57%	8.61%
MFI	67 Neutral	C$3.28B	18.22	11.72%	3.04%	-0.03%	497.79%
PBH	67 Neutral	C$4.27B	45.49	3.86%	3.44%	13.05%	-33.72%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
KPT	59 Neutral	C$94.28M	21.26	5.55%	6.86%	―	-39.19%

KP Tissue Corporate Events

KP Tissue Declares Quarterly Dividend and Offers Reinvestment Plan

KP Tissue Inc. announced a quarterly dividend of $0.18 per common share, payable on April 15, 2025, to shareholders of record as of March 31, 2025. This dividend declaration aligns with a corresponding distribution by Kruger Products Inc., in which KPT holds a limited partnership interest. Additionally, KP Tissue offers a Dividend Reinvestment Plan (DRIP) for Canadian shareholders, allowing them to reinvest cash dividends into additional common shares. This announcement underscores KPT’s commitment to providing shareholder value and maintaining its strategic investment in Kruger Products, a key player in the North American tissue market.

KP Tissue Achieves Record Revenue in 2024 Amid Expansion Plans

KP Tissue Inc. reported record revenue exceeding $2 billion for 2024, with strong Adjusted EBITDA across all quarters, despite challenges like volatile pulp prices. The company is exploring the construction of a new manufacturing facility to enhance its market share and product offerings in North America. Additionally, KP Tissue is preparing contingency plans to address potential U.S. tariffs and is leveraging patriotic consumer sentiment in Canada through marketing campaigns.